Your AI Pilot Worked. Now Comes the Hard Part.

How do pharmaceutical companies move AI from pilot to enterprise adoption? They build organizational confidence around a proven use case, connect it to real workflows, establish governance and ownership, engage users, and sustain measurable value at scale.

The Signal

Many life sciences organizations are moving quickly to explore AI. Pilots are being launched, use cases are being tested, and early results are generating real excitement.

But then reality sets in. The pilot worked, and momentum stalls. Moving from a successful pilot to enterprise adoption is where many AI initiatives get stuck. The challenge is rarely the technology. It’s what happens when AI meets the realities of a complex, regulated, and highly matrixed organization.

Why It Matters

A pilot can demonstrate that a specific use case can work. It can show potential for efficiency, better insights, or improved decision-making. That’s important. It builds credibility and helps create internal interest.

But a pilot typically operates in a controlled environment with a small group of users, a focused dataset and high attention from the project team. Enterprise adoption is a very different challenge. It requires integration, governance, organizational readiness, user adoption and a sustainable operating model.

Once the pilot is complete, organizations often encounter familiar questions: How does this integrate with our systems? How do we manage the data? What are the regulatory and compliance implications? Who is accountable? How do we drive adoption across a broader set of users? And most importantly, how do we prove and sustain measurable value at scale?

These aren’t reasons to slow down. They are the realities of moving from experimentation to enterprise impact.

The Curbside View

At RISE, we see AI adoption as a progression, not a single step. Organizations move from possibility to proof, but the real work begins as they build organizational confidence, drive adoption and achieve measurable value at scale.

Each stage requires different leadership, capabilities and change management. Success depends on connecting the technology to the business, the people and the operating model. The real opportunity is to build the capabilities, confidence and operating models that turn early success into sustained enterprise value.

The Move

Before expanding a successful pilot, make the path to adoption explicit. Use the Enterprise AI Adoption Map™ for Pharma + Biotech to examine where the organization is ready and where the next barrier will appear.

1. Define the value. Name the business outcome, the workflow it improves and the measure that will show whether the change lasts.
2. Test the operating conditions. Check representative data, integration needs, exceptions, governance and human review beyond the controlled pilot.
3. Build organizational confidence. Align the business owner, technology, legal, compliance, managers and users on accountability and acceptable risk.
4. Plan for sustained use. Equip teams, track adoption and expand only when the workflow delivers measurable value in everyday conditions.

Explore RISE’s AI in Life Sciences expertise, listen to the RISE Unpacked conversation on enterprise AI adoption, or contribute your perspective to The RISE Index™ research.

One Question to Take With You